Outcomes of Skin Grafting in Patients Taking Anticoagulants

Kristen Aliano MD; Jessica Korsh MS; Thomas Davenport MD, FACS

Winthrop University Hospital Long Island Plastic Surgical Group





Disclosure of Relevant Financial Interests

Nothing to Disclose

Background


- Surgical patients may have serious medical problems including atrial fibrillation, myocardial infarction, deep vein thrombosis, pulmonary embolism, and stroke.
- These patients may be taking anticoagulant medications such as clopidogrel, aspirin, warfarin, and enoxaparin.

Background

- Little research has been published regarding the perioperative use of anticoagulants in patients undergoing skin grafting.
- There are no current guidelines regarding the use of anticoagulant medications in these patients.

Objectives

To investigate the surgical complications in skin graft patients taking medications that inhibit primary or secondary hemostasis.





Methods

We conducted a retrospective chart review using ICD-9 codes of all patients who underwent skin grafting by one plastic surgeon at Winthrop University Hospital over the course of two years.



Results: Patient Population

- 83 patients who received skin grafts were identified using ICD-9 code search
 - 19 of these patients were taking anticoagulant medications
 - ▶ 12 Females
 - > 7 Males
 - Mean age: 75.4 years

Results: Patients by Type of Anticoagulant Medication

- Warfarin
- Aspirin
- Clopidogrel
- Warfarin and enoxaparin
- Warfarin and clopidogrel
- Clopidogrel and aspirin



Results: Medical Conditions

- Conditions for which patients received anticoagulant therapy:
 - Atrial fibrillation
 - Cardiovascular diseases
 - > Stroke
 - Factor V Leiden
 - Essential thrombocytosis

Outcomes

- All patients underwent successful skin grafting with vacuum-assisted wound closure device placement.
 - No graft losses reported
 - No blood transfusions required
 - No seromas or hematomas
 - No donor site complications



Discussion

Approximately 25% of patients undergoing dermatological surgery take antithrombotic medications.

- Incidence of bleeding complications in dermatological surgery is low.
- There is little evidence to suggest that patients should discontinue anticoagulant use prior to cutaneous surgery.

Discussion

- In our patient cohort there appeared to be no increased risk of hemostatic complications in patients taking anticoagulant medications while undergoing skin grafting.
- There were no reported complications, hemostatic or otherwise.

Discussion

- Clinicians must balance the risks and benefits of allowing patients to use anticoagulant medications perioperatively.
- The lack of complications in our study suggests that the risks of discontinuing these medications may outweigh the benefits.

References

- Henley J and Brewer JD. Newer hemostatic agents used in the practice of dermatologic surgery. Dermatol Res Pract. 2013;2013:279289. doi: 10.1155/2013/279289. Epub 2013 Aug 7.
- Khaliffe MR and Redett RJ. The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidencebased recommendations. Plast Reconstr Surg 2006; <u>118</u>: 110e-116e.
- Callahan S, Goldsberry A, Kim G, and Yoo S. The management of antithrombotic medication in skin surgery. Dermatological Surgery 2012; 38: 1418-1426.
- Bartlett GR. Does aspirin affect the outcome of minor cutaneous surgery? Br J Plast Surg 1999;52:214–16.
- Goldsmith SM, Leshin B, Owen J. Management of patients taking anticoagulans and platelet inhibitors prior to dermatologic surgery. J Dermatol Surg Oncol 1993; 19:578-581.